

Menarini Biotech

For Your Molecule from Gene to Clinic on to Commercialisation



With over 25 years of industry excellence, Menarini Biotech has transitioned from a powerhouse in internal projects to your go-to CDMO for cutting-edge solutions.

Our seasoned team of top-class professionals, coupled with state-of-the-art facilities, ensures that your project receives nothing short of exceptional attention and expertise.

- Established in 2003
- Located in greater Rome area, Italy
- 80 employees
- Custom Services include PD, AD, GMP Manufacture of Biologics #mAbs, #ADCs, #BsMAbs, #fusion proteins ... and #more
- AIFA approved
- ❖ Background in CDMO, Pharma, Biotech

Who we are





Why Work with Menarini Biotech

- Financially stable (family owned)
- Short lead times to start project
- Leverage in-house (Menarini Group) R+D expertise
- Flexible, agile
- **❖** Based in EU
- ❖ Intimate Customer Relationship we care.
- Faster Timelines (Execution, Responsiveness) than Your previous CDMO





Quality First

30 people in QA, RA, QC, and AD


>30 years of Experience

Added Value for You:

- 18 years of Successful GMP Inspection
- Authorised for clinical mfg. phase 1-3
- Authorised for QC testing of DP
- Support IMPD/IND filing
- Site documentation, Deviation and Change Control management to go paperless
- CFR 21 part 11 compliant lab software (e.g. Empower-LabX)
- ❖ GAMP 5.2 compliant Electronic Validation Protocol



Key Performance Data



04/04/2024 Menarini Biotech



PD: 20+ Years of Track Record Built in Various TAs



Oncology

mAbs including BsAbs, produced in hybridoma and CHO cells; plasmide vaccines produced in bacteria Recombinant human apoptosis mediators produced in CHO cells




Cardiovascular disease

Recombinant enzymes




Inflammation

Recombinant enzymes



Enzyme replacement therapy Recombinant enzymes



Haemopoiesis

Recombinant human cytokines produced in CHO



Upstream Development 2L-50L

- Cell Line Development (CLD): experience with e.g. Potelligent, CHO GS, Expi-CHO S, DG44, hybridoma
- ❖ Basal media screening, selection, and optimization
- ❖ Feed media screening, selection and optimization





- Production bioreactor growth parameter screening, selection and optimization
- Harvest filtration selection and optimization
- We make extensive use of statistics (DoE, PCA, Multivariate Data Analysis) for all development activities



Downstream Development

- ReFiltration (dead end, nano, tangential) screening, selection and optimization
- Formulation screening and selection
- Resin screening, selection, and optimization






- Intermediate hold studies
- Process optimization and characterization
- Established analytical and DSP platforms



From DNA to GMP (CoA) in 9-12 Months





Timeline of 9 to 12 months from DNA Sequence to GMP

MENARINI BIOTECH 8.r.1

QC: Well-Equipped for Your Next Challenge



Process-related impurities/Contaminants
Product-related impurities
Protein characterisation
Comparability Study
Stability Study
Forced Degradation Study
Validation of Analytical Methods
Batch Certification
Established analytical and DSP platforms


SLS/FLR System 04/04/2024

Menarini Biotech



Simplified Workflows to make Your Molecule on-Time and In-Full

Clinical and Early
Commercial
GMP Manufacturing
In Single-Use Equipment



USP area:

Grade D 390m² BSL-2

Media and buffer preparation

3x200L (XDR-200) 2x1kL (STR 1000 3rd gen. SUB)



DSP area:

Grade C
240m²
BSL-1
Buffer preparation
Column packing
Filling into manifold system bags



Three Dedicated Workshops for HPAPIs, ADCs, and non-toxic APIs







Highly toxic payloads up to 200g scale

GMP Mfg.: Two separate facilities for Anticancer and for Standard non-toxic API

Full SCM including linker technology (incl. mfg. of linker), tech transfers

Sound knowledge of the current ADC conjugation technology

Temperature controlled storage of API (controlled 15-25 °c, 2-8 °C, -20°C)

OEL up to OEB 5



Pleased to Discuss your next Challenge.

Please contact:

Heiko Richtzenhain

Mail: hrichtzenhain@menarini-biotech.it

Tel: +41 79 788 6527